Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regulus Therapeutics

8.16
+0.05100.63%
Volume:467.19K
Turnover:3.80M
Market Cap:564.95M
PE:-11.28
High:8.20
Open:8.18
Low:8.07
Close:8.11
Loading ...

Preston Klassen, President & Head of R&D, Reports Acquisition of Common Shares in Regulus Therapeutics Inc

Reuters
·
05 Jun

Novartis Ag - Novartis Announces Commencement of Tender Offer to Acquire Regulus Therapeutics

THOMSON REUTERS
·
27 May

Novartis Launches Tender Offer to Acquire Regulus Therapeutics for $7.00 Per Share Plus Contingent Value Right

Reuters
·
27 May

Novartis Ag - Offer Includes $7.00 Cash per Share Plus Contingent Value Right

THOMSON REUTERS
·
27 May

Novartis Ag - Offer Subject to Customary Conditions Including Hart-Scott-Rodino Act

THOMSON REUTERS
·
27 May

Novartis Ag - Offer to Expire on June 24, 2025

THOMSON REUTERS
·
27 May

Regulus Resources Inc. Unveils Corporate Presentation Highlighting AntaKori Copper-Gold Project and Long-Term Strategy

Reuters
·
21 May

Regulus Therapeutics Q1 EPS $(0.15) Beats $(0.24) Estimate

Benzinga
·
09 May

Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Regulus Therapeutics Reports Increased R&D and G&A Expenses in Q1 2025; Cash Runway Extends to Early 2026

Reuters
·
09 May

Regulus Therapeutics Q1 Basic EPS USD -0.15

THOMSON REUTERS
·
09 May

Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
06 May

Novartis to buy Regulus Therapeutics for as much as $1.7 billion

LA Times
·
02 May

Biotech Alert: Searches spiking for these stocks today

TipRanks
·
02 May

Regulus Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo

Dow Jones
·
01 May

Oppenheimer Downgrades Regulus Therapeutics to Market Perform From Outperform

MT Newswires Live
·
01 May

Regulus Therapeutics Inc : Wells Fargo Cuts to Equal Weight From Overweight; Raises Target Price to $9 From $6

THOMSON REUTERS
·
01 May

U.S. RESEARCH ROUNDUP-Avepoint, Meta, United Therapeutics

Reuters
·
01 May

Regulus Therapeutics Inc : Leerink Partners Cuts to Market Perform From Outperform; Raises Target Price to $7 From $6

THOMSON REUTERS
·
01 May

Regulus Therapeutics Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
01 May